Companies / Health Care / Health Care Equipment
Abbott Laboratories stock buybacks
ABT$793Mbought back in the 12 months to Mar 31, 2026
Abbott Laboratories bought back $793M of its stock in the last twelve months, $101M more than it paid out in stock compensation. Its share count is down 0.0% from a year earlier.
Show as table
| Period | Value |
|---|---|
| Q2 '20 | $4M |
| Q3 '20 | $2M |
| Q4 '20 | $161M |
| Q1 '21 | $275M |
| Q2 '21 | $471M |
| Q3 '21 | $579M |
| Q4 '21 | $974M |
| Q1 '22 | $2.3B |
| Q2 '22 | $5M |
| Q3 '22 | $798M |
| Q4 '22 | $685M |
| Q1 '23 | $540M |
| Q2 '23 | $426M |
| Q3 '23 | $2M |
| Q4 '23 | $259M |
| Q1 '24 | $226M |
| Q2 '24 | $3M |
| Q3 '24 | $751M |
| Q4 '24 | $315M |
| Q1 '25 | $280M |
| Q2 '25 | $6M |
| Q3 '25 | $305M |
| Q4 '25 | $302M |
| Q1 '26 | $180M |
Show as table
| Period | Value |
|---|---|
| Q2 '20 | 1.79B |
| Q3 '20 | 1.79B |
| Q4 '20 | 1.79B |
| Q1 '21 | 1.79B |
| Q2 '21 | 1.79B |
| Q3 '21 | 1.79B |
| Q4 '21 | 1.78B |
| Q1 '22 | 1.77B |
| Q2 '22 | 1.77B |
| Q3 '22 | 1.76B |
| Q4 '22 | 1.75B |
| Q1 '23 | 1.75B |
| Q2 '23 | 1.75B |
| Q3 '23 | 1.75B |
| Q4 '23 | 1.75B |
| Q1 '24 | 1.75B |
| Q2 '24 | 1.75B |
| Q3 '24 | 1.75B |
| Q4 '24 | 1.74B |
| Q1 '25 | 1.75B |
| Q2 '25 | 1.75B |
| Q3 '25 | 1.75B |
| Q4 '25 | 1.74B |
| Q1 '26 | 1.75B |
$180Mlast quarter (Q1 2026)
$101Mnet of stock compensation ($692M)
−0.0%diluted shares, 1 year
−2.1%diluted shares, 5 years
$4.2Bdividends, 12 months
11%of free cash flow ($7.4B) spent on buybacks
$0raised by issuing stock, 12 months
1.74Bshares outstanding (Mar 31, 2026)
Abbott Laboratories’s 10-Q for the period ending Jun 30, 2026 (filed Jul 28, 2026) isn’t in the SEC’s structured data yet, so figures here run through Mar 31, 2026. Read the new filing.
By fiscal year
Questions
- Does Abbott Laboratories buy back its stock?
- Abbott Laboratories bought back $793M of its stock in the last twelve months, $101M more than it paid out in stock compensation. Its share count is down 0.0% from a year earlier.
- How much did Abbott Laboratories spend on buybacks in fiscal 2025?
- $893M, according to its 10-K for the fiscal year ending Dec 31, 2025.
- Is Abbott Laboratories's share count going down?
- Its diluted share count changed −2.1% over five fiscal years and −0.0% over the last year.
Latest filing used: 10-Q for the period ending Jun 30, 2026, filed Jul 28, 2026 · open on SEC.gov